Citations

Showing 10 of 108135 citations.

Eculizumab monotherapy for NMOSD: Data from PREVENT and its open-label extension
Pittock, Sean J. , Palace, Jacqueline , Kim, Ho Jin , Nakashima, Ichiro , Levy, Michael , Shang, Shulian, Yountz, Marcus, Miller, Larisa , Armstrong, Róisín, Wingerchuk, Dean M. , Group, the PREVENT Study, Palace, Jacqueline , Kim, Ho Jin , Oreja-Guevara, Celia , Nakashima, Ichiro , Levy, Michael , Pittock, S J , Palace, Jacqueline , Fujihara, Kazuo , Berthele, Achim , Oreja‐Guevara, Celia , Group, the PREVENT Study

Mayo Clinic

Multiple Sclerosis Journal | September 9, 2021 | Volume: 28 | Issue: 3 | Pages: 480-486

10.1177/13524585211038291 | PMID 34498507 Get It

During PREVENT (a phase 3, randomized, double-blind, placebo-controlled, time-to-event study) and its open-label extension (interim analysis), 33 adults with aquaporin-4 immunoglobulin G-positive neuromyelitis optica spectrum disorder (AQP4-IgG + NMOSD) received eculizumab monotherapy for a median of 2.8 years (range, 14 weeks–5.2 years). At 192 weeks (~4 years), 96% of these patients were free from adjudicated relapses (Kaplan–Meier analysis; 95% confidence interval, 75.7–99.4). During PREVENT, 95% (20/21) of patients receiving eculizumab monotherapy had no disability worsening. Eculizumab monotherapy provides effective long-term relapse prevention, relieving the chronic immunosuppression burden in patients with AQP4-IgG + NMOSD. ClinicalTrials.gov; PREVENT: NCT01892345; open-label extension: NCT02003144.
Optimal management of acute decompensated aortic stenosis
Jneid, Hani , Jneid, Hani , Alkhouli, Mohamad

Mayo Clinic

Catheterization and Cardiovascular Interventions | September 9, 2021 | Volume: 98 | Issue: 3 | Pages: 613-614

10.1002/ccd.29878 | PMID 34498391 Get It

Key Points The optimal management of acute decompensated aortic stenosis (AS) remains a clinical conundrum. Urgent transcatheter aortic valve implantation (TAVI) is feasible and associated with lower readmissions rates than urgent balloon aortic valvuloplasty. In contemporary practice, TAVI may be the treatment of choice of patients admitted with acute decompensated AS.
Characteristics of paediatric weight management in the United States: Associations with program retention and BMI outcomes in the paediatric obesity weight evaluation registry ( PO
Tucker, Jared M. , Stratbucker, William, King, Eileen, Cuda, Suzanne , Negrete, Sylvia , Sweeney, Brooke , Kumar, Seema , Borzutzky, Claudia , Binns, Helen J. , Kirk, Shelley, Group, The POWER Work, Group, The POWER Work

Mayo Clinic

Pediatric Obesity | September 9, 2021 | Volume: 17 | Issue: 2 | Pages: No page available

10.1111/ijpo.12848 | PMID 34498814 Get It

Summary Objective To describe characteristics of paediatric weight management (PWM) programs across the United States and evaluate associations with program‐specific retention rates and body mass index (BMI) outcomes at 6 months. Methods A program profile survey was administered to 33 programs within the Paediatric Obesity Weight Evaluation Registry (POWER) to assess program staffing, services, and treatment format. Patient retention and percent of the 95th BMI percentile (%BMIp95) changes were assessed for each program. Results At 6 months program retention rates ranged from 15% to 74% (median: 41%), and program %BMIp95 changes ranged from −9.0 to +0.5 percentage points (median: −1.7). Percent of patients with ≥5 percentage‐point decrease in %BMIp95 ranged from 17% to 71% across programs (median: 29%). No associations were detected between program characteristics and retention or %BMIp95 changes. Conclusions Six‐month patient retention and BMI outcomes vary substantially in PWM programs across the United States. Yet, no associations were found between PWM treatment factors and these program‐level patient outcomes.
Respiratory diseases in patients with bed bugs
Sheele, Johnathan M.

Mayo Clinic

The Clinical Respiratory Journal | September 9, 2021 | Volume: 16 | Issue: 1 | Pages: 27-34

10.1111/crj.13447 | PMID 34498401 Get It

AbstractIntroductionSome arthropods such as cockroaches can exacerbate asthma, but it is unknown is this is true of bed bugs.ObjectivesThe objective of this work is to determine if bronchospastic diseases like asthma and chronic obstructive pulmonary disease (COPD) would be higher for ED patients who have bed bug infestation compared with patients who do not have bed bug infestation.MethodsA case–control study was performed with 332 adult emergency department (ED) patients with bed bug infestation and 4952 without infestation. Univariable and multivariable regression analysis was performed.Results and ConclusionPatients with bed bug infestation were not more likely to have a past history of or an ED diagnosis of asthma or chronic obstructive pulmonary disease (COPD). However, bed bug infested patients were significantly more likely to undergo chest radiography, be admitted to the hospital, and receive albuterol in the ED (P < 0.05). Infested patients receiving albuterol in the ED were more likely to be admitted to the hospital compared with uninfested patients receiving albuterol (P < 0.001). Patients with an ED or inpatient diagnosis of asthma or COPD and bed bugs (compared with those without bed bugs) had significantly more ED visits during the study (P < 0.03). Bed bug infestations may be associated with respiratory pathology, which requires further investigation.
Extending human healthspan and longevity: a symposium report
DeVito, Loren M., Barzilai, Nir , Niedernhofer, Laura J. , Milman, Sofiya , Ferrucci, Luigi , Kuchel, George A. , Mannick, Joan B. , Gonzales, Mitzi M. , Kirkland, James L. , Campisi, Judith , Niedernhofer, Laura J , Ferrucci, Luigi , Kuchel, George A , Gonzales, Mitzi , Cuervo, Ana M , Levine, Morgan E. , Promislow, Daniel , Justice, Jamie N. , Cohen, Pinchas

Mayo Clinic

Annals of the New York Academy of Sciences | September 9, 2021 | Volume: 1507 | Issue: 1 | Pages: 70-83

10.1111/nyas.14681 | PMID 34498278 Get It

AbstractFor many years, it was believed that the aging process was inevitable and that age‐related diseases could not be prevented or reversed. The geroscience hypothesis, however, posits that aging is, in fact, malleable and, by targeting the hallmarks of biological aging, it is indeed possible to alleviate age‐related diseases and dysfunction and extend longevity. This field of geroscience thus aims to prevent the development of multiple disorders with age, thereby extending healthspan, with the reduction of morbidity toward the end of life. Experts in the field have made remarkable advancements in understanding the mechanisms underlying biological aging and identified ways to target aging pathways using both novel agents and repurposed therapies. While geroscience researchers currently face significant barriers in bringing therapies through clinical development, proof‐of‐concept studies, as well as early‐stage clinical trials, are underway to assess the feasibility of drug evaluation and lay a regulatory foundation for future FDA approvals in the future.
Receptivity to a Nurse-Led Symptom Management Intervention Among Highly Symptomatic Patients With Cancer
Wintheiser, Grant , Ruddy, Kathryn J. , Herrin, Jeph , Rahman, Parvez, Pachman, Deirdre R. , Leppin, Aaron L. , Lee, Minji K. , Tofthagen, Cindy , Wintheiser, Grant A , Rahman, Parvez A, Lee, Minji K , Tofthagen, Cindy S , Chlan, Linda L , Ridgeway, Jennifer L , Mitchell, Sandra A , Herrin, Jeph , Rutten, Lila J. Finney , Griffin, Joan M. , Chlan, Linda L. , Ridgeway, Jennifer L. , Cheville, Andrea

Mayo Clinic

JNCI: Journal of the National Cancer Institute | September 9, 2021 | Volume: 114 | Issue: 3 | Pages: 458-466

10.1093/jnci/djab172 | PMID 34508602 Get It

Abstract Background The symptom burden associated with cancer and its treatment can negatively affect patients’ quality of life and survival. Symptom-focused collaborative care model (CCM) interventions can improve outcomes, but only if patients engage with them. We assessed the receptivity of severely symptomatic oncology patients to a remote nurse-led CCM intervention. Methods In a pragmatic, cluster-randomized, stepped-wedge trial conducted as part of the National Cancer Institute IMPACT Consortium (E2C2, NCT03892967), patients receiving cancer care were asked to rate their sleep disturbance, pain, anxiety, emotional distress, fatigue, and limitations in physical function. Patients reporting at least 1 severe symptom (≥7/10) were offered phone consultation with a nurse symptom care manager (RN SCM). Initially, patients had to “opt-in” to receive a call, but the protocol was later modified so they had to “opt-out” if they did not want a call. We assessed the impact of opt-in vs opt-out framing and patient characteristics on receptiveness to RN SCM calls. All statistical tests were 2-sided. Results Of the 1204 symptom assessments (from 864 patients) on which at least 1 severe symptom was documented, 469 (39.0%) indicated receptivity to an RN SCM phone call. The opt-out period (odds ratio [OR] = 1.61, 95% confidence interval [CI] = 1.12 to 2.32, P = .01), receiving care at a tertiary care center (OR = 3.59, 95% CI = 2.18 to 5.91, P &lt; .001), and having severe pain (OR = 1.80, 95% CI = 1.24 to 2.62, P = .002) were associated with statistically significantly greater willingness to receive a call. Conclusions Many severely symptomatic patients were not receptive to an RN SCM phone call. Better understanding of reasons for refusal and strategies for improving patient receptivity are needed.
Integrating Genome and Methylome Data to Identify Candidate DNA Methylation Biomarkers for Pancreatic Cancer Risk
Zhu, Jingjing , Yang, Yaohua , Kisiel, John B. , Michaud, Dominique S. , Shu, Xiao-Ou , Liu, Duo , Li, Bingshan , Tao, Ran , Wu, Lang , Mahoney, Douglas W. , Shu, Xiao-Ou , Cai, Qiuyin , Zheng, Wei , Kisiel, John B , Michaud, Dominique S , Guo, Xingyi , Taylor, William R. , Shu, Xiao‐Ou , Cai, Qiuyin , Zheng, Wei , Long, Jirong , Yang, Yaohua

Mayo Clinic

Cancer Epidemiology, Biomarkers & Prevention | September 9, 2021 | Volume: 30 | Issue: 11 | Pages: 2079-2087

10.1158/1055-9965.epi-21-0400 | PMID 34497089 Get It

AbstractBackground:The role of methylation in pancreatic cancer risk remains unclear. We integrated genome and methylome data to identify CpG sites (CpG) with the genetically predicted methylation to be associated with pancreatic cancer risk. We also studied gene expression to understand the identified associations.Methods:Using genetic data and white blood cell methylation data from 1,595 subjects of European descent, we built genetic models to predict DNA methylation levels. After internal and external validation, we applied prediction models with satisfactory performance to the genetic data of 8,280 pancreatic cancer cases and 6,728 controls of European ancestry to investigate the associations of predicted methylation with pancreatic cancer risk. For associated CpGs, we compared their measured levels in pancreatic tumor versus benign tissue.Results:We identified 45 CpGs at nine loci showing an association with pancreatic cancer risk, including 15 CpGs showing an association independent from identified risk variants. We observed significant correlations between predicted methylation of 16 of the 45 CpGs and predicted expression of eight adjacent genes, of which six genes showed associations with pancreatic cancer risk. Of the 45 CpGs, we were able to compare measured methylation of 16 in pancreatic tumor versus benign pancreatic tissue. Of them, six showed differentiated methylation.Conclusions:We identified methylation biomarker candidates associated with pancreatic cancer using genetic instruments and added additional insights into the role of methylation in regulating gene expression in pancreatic cancer development.Impact:A comprehensive study using genetic instruments identifies 45 CpG sites at nine genomic loci for pancreatic cancer risk.
Role of infectious diseases pharmacists in outpatient intravenous and complex oral antimicrobial therapy: Society of Infectious Diseases Pharmacists insights
Rivera, Christina G. , Mehta, Meera, Ryan, Keenan , Tucker, Kendall J , Ryan, Keenan L , Rivera, Christina G , Stevens, Ryan W. , Mahoney, Monica V.

Mayo Clinic

JACCP: JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY | September 8, 2021 | Volume: 4 | Issue: 9 | Pages: 1161-1169

10.1002/jac5.1473 Get It

AbstractOutpatient parenteral antimicrobial therapy (OPAT) is a well‐established mechanism to facilitate patient discharge, lower inpatient admission cost, and decrease the risk of health care–acquired infections. Although there are numerous benefits to patients and health care institutions, OPAT is complex and not without risks. Patients may be discharged on long courses of oral antimicrobials, known as complex outpatient antimicrobial therapy (COpAT), which also requires careful monitoring and oversight. This, coupled with the need for antimicrobial stewardship across the continuum of care, positions pharmacists with infectious diseases (ID) training as crucial leaders in the field of OPAT. The development, implementation, and maintenance of these services requires the careful attention of health care personnel in discharge antimicrobial selection, continuity of care at key care transitions, implementation of optimal care bundles, provision of thorough patient education throughout the OPAT process, coordination with a multidisciplinary team including home infusion and nursing, and monitoring of program metrics to determine successes and opportunities for improvement. Ongoing support for optimal delivery of patient care will be required as OPAT practice, and health care delivery at large, continues to evolve. This involves continued advocacy for collaborative practice development, optimizing payment for nondispensatory OPAT services, and integration of effective telehealth programs. This article summarizes the need for practice expansion of ID pharmacist specialists in OPAT/COpAT management across the care continuum and best practices for establishment of these services.
Stanley A. Klatsky, M.D., 1934 to 2020
Singer, Robert J., Bernard, Bob, Chandawarkar, Akash, Manson, Paul N., Singer, Robert

Mayo Clinic

Plastic & Reconstructive Surgery | September 8, 2021 | Volume: 148 | Issue: 4 | Pages: 930-933

10.1097/prs.0000000000008337 Get It

Autologous and allogeneic hematopoietic cell transplantation for diffuse large B-cell lymphoma–type Richter syndrome
Herrera, Alex F. , Ahn, Kwang Woo , Litovich, Carlos, Chen, Yue , Assal, Amer , Bashir, Qaiser , Bayer, Ruthee-Lu , Coleman, Melanie, DeFilipp, Zachariah , Farhadfar, Nosha , Greenwood, Matthew , Hahn, Theresa , Horwitz, Mitchell E. , Jacobson, Caron A. , Lachance, Sylvie, Langston, Amelia , Mattar, Bassam, Mian, Mohammad , Nathan, Sunita , Phillips, Adrienne A. , Rakszawski, Kevin , Sengeloev, Henrik, Shenoy, Shalini , Sauter, Craig S. , Kharfan‐Dabaja, Mohamed A. , Jaglowski, Samantha , Langston, Amelia , McGuirk, Joseph , Kharfan-Dabaja, Mohamed A , Hamadani, Mehdi , Assal, Amer , Lachance, Sylvie, Maziarz, Richard Thomas , McGuirk, Joseph P. , Stuart, Robert K. , Hamadani, Mehdi

Mayo Clinic

Blood Advances | September 8, 2021 | Volume: 5 | Issue: 18 | Pages: 3528-3539

10.1182/bloodadvances.2021004865 | PMID 34496026 Get It

Abstract Richter syndrome (RS) represents a transformation from chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) to aggressive lymphoma, most commonly diffuse large B-cell lymphoma (DLBCL), which is associated with a dismal prognosis. Patients with DLBCL-RS have poor outcomes with DLBCL-directed therapy; thus, consolidation with hematopoietic cell transplantation (HCT) has been used, with durable remissions observed. Studies reporting HCT outcomes in patients with DLBCL-RS have been small, have not evaluated the prognostic impact of cytogenetic risk factors, and were conducted prior to the era of novel targeted therapy of CLL/SLL. We performed a Center for International Blood and Transplant Research registry study evaluating outcomes after autologous HCT (auto-HCT; n = 53) and allogeneic HCT (allo-HCT; n = 118) in patients with DLBCL-RS treated in the modern era. More auto-HCT recipients were in complete response (CR) at HCT relative to allo-HCT recipients (66% vs 34%), whereas a higher proportion of allo-HCT recipients had 17p deletion (33% vs 7%) and had previously received novel agents (39% vs 10%). In the auto-HCT cohort, the 3-year relapse incidence, progression-free survival (PFS), and overall survival (OS) were 37%, 48%, and 57%, respectively. Among allo-HCT recipients, the 3-year relapse incidence, PFS, and OS were 30%, 43%, and 52%, respectively. In the allo-HCT cohort, deeper response at HCT was associated with outcomes (3-year PFS/OS, 66%/77% CR vs 43%/57% partial response vs 5%/15% resistant; P &lt; .0001 for both), whereas cytogenetic abnormalities and prior novel therapy did not impact outcomes. In our study, HCT resulted in durable remissions in therapy-sensitive patients with DLBCL-RS treated in the era of targeted CLL/SLL therapy, including patients with high-risk features.